Parkinson's Institute | GenomeWeb

Parkinson's Institute

IO Informatics has begun beta testing a new iteration of the Sentient software suite with pharma partners ahead of a formal launch planned for the first quarter of 2016.

NEW YORK (GenomeWeb News) – Berg Pharma will use its Integrative Biology platform to identify drug targets and biomarkers in clinical samples from the Parkinson's Institute of Sunnyvale, Calif., under a partnership announced today.

A 23andMe and Parkinson's Institute team has tracked down two new risk loci for Parkinson's disease and verified many more through a web-based genome-wide association study involving more than 3,400 cases and nearly 30,000 controls.

The subsidiary, called Arrayit Diagnostics, will use its parent's chip platform to identify genomic and proteomic biomarkers for specific diseases, with the aim of making early-stage diagnoses.

The institute will use the company's microarray platform to find markers related to Parkinson's disease.

The partners will use ArrayIt's new microarray technology in looking for Parkinson's biomarkers.



Alzheimer's Disease Neuroimaging Initiative, OncoMethylome Sciences, Merck KGaA, 23andMe, Michael J. Fox Foundation for Parkinson's Research, Parkinson's Institute and Clinical Center, and more …

Short Reads


University of Illinois at Urbana-Champgain, 23andMe, Michael J. Fox Foundaton for Parkinson's Research, Parkinson's Institute and Clinical Center, SeqWright, Roche NimbleGen, Chronix Biomedical, Genome Atlantic, Agilent Technologies

Working to enroll thousands of individuals with Parkinson's into an online community, Sergey Brin, 23andMe, the Michael J. Fox Foundation, and the Parkinson's Institute are teaming up to offer 23andMe services at a bargain price.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.